Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levamisole added to corticosteroids for first-episode childhood idiopathic nephrotic syndrome
NL-OMON55651Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) comparing Levamisole plus prednisolone with Placebo plus prednisolone (2 arms). Primary endpoint: Occurrence of first relapse within 12 months after randomization. Started Apr 2018; status: recruiting.
02
Drugs
levamisole
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NL-OMON55651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55651.